RE:Impacted by end of agrements in LATAM- is this only Gilead ?There were a few factors offsetting growth this quarter:
- No covid sales and no Gilead sales ($10.5M)
- Lower levels of Exelon sales due to advande buying in the last quarter ($2M)
- Lower levels of branded generics sales due to new competition
Out of these, I would consider the branded generics a negative... but it's difficult to say how significant it is. I wish someone would have asked about this during the call.
If we look at the numbers by therapeutic area:
- Oncology grew nicely (key products) especially when you consider the growth was offset by whatever decline we had from branded generics. Key products grew at least 14% (plus whatever the decline from branded generics was).
- Infectious Diseases had great growth if you exclude covid and Gilead sales from last year's numbers. It went from $20.5M to $27.3M = 33% growth!
- Seems like Exelon sales were basically the same as last year if you take the $2M of advance sales into account. Hopefully they can start achieving growth here now that they've been handed the keys.
A good level of operating cash flow, by the way, even with a $4M+ increase in working capital (with a further increase expected during the ongoing quarter).